NCT05835999View on ClinicalTrials.gov

Everolimus Aging Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
AgingInsulin Resistance
Interventions
DRUG

Everolimus 0.5 MG once per day

Everolimus is considered an mTOR kinase inhibitor

DRUG

Everolimus 5 MG once per week

Everolimus is considered an mTOR kinase inhibitor

DRUG

Placebo once per day

No therapeutic effect

DRUG

Placebo once per week

No therapeutic effect

Trial Locations (1)

53705

RECRUITING

University of Wisconsin-Madison, Madison

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Wisconsin, Madison

OTHER